Annexon Biosciences’ primary focus is inhibiting C1q, the initiating molecule of the classical complement pathway, to prevent complement ... organelles within cells that organize and regulate ...
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with so-called “HER2-ultralow” status. The company’s PATHWAY HER2 ...
Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5 ...
PATHWAY HER2 (4B5) test standardizes IHC processes, reducing variability and ensuring reliable results, enhancing clinical decision-making. Roche aims to solidify leadership in HER2 diagnostics ...
Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback